Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

July 19, 2022

Trial Will Investigate Drug to Curb Cancer Treatment-Related Anorexia, Weight Loss

Author(s):

Brielle Benyon

ART27.13 may help increase appetite in patients undergoing cancer treatment.

Patients in three groups of the Cancer Appetite Recovery Study (CAReS) have been enrolled, launching the phase 1b trial of ART27.13 to increase appetite and food intake in patients who are experiencing anorexia (inability to eat) and weight loss as a result of cancer treatment, according to Artelo Biosciences Inc, the pharmaceutical company running the trial.

Prior phase 1 trials of ART27.13 conducted by the pharmaceutical company AstraZeneca showed that the supportive therapy, which works by targeting cannabinoid receptors, led to a statistically significant increase in body weight in healthy individuals.

“The CAReS safety review committee has reviewed the data thus far and has concluded that ART27.13 has been well-tolerated with no serious adverse events attributable to the investigational drug in patients suffering from anorexia associated with cancer,” said Dr. Steven D. Reich, chief medical officer of Artelo, in a press release.

READ MORE: Cancer Survivors Share Their Eating Struggles — and Solutions — for Life After Cancer Treatment

The CAReS trial will analyze the safety of increasing doses of ART27.13. Researchers will then take that data to determine the best dose for phase 2a of the study, which will further analyze safety as well as how well the drug works.

So far, research has shown that ART27.13 is well-tolerated, and there have been no dose reductions, dose interruptions or medical interventions needed from the drug’s side effects.

“Remarkably, the safety profile of ART27.13 appears more benign among (patients with cancer) participating in CAReS than observed in healthy volunteers in prior phase 1 studies,” Reich said. “Furthermore, we have seen pharmacokinetics consistent with the AstraZeneca experience and an improvement in anorexia from each dose escalation.”


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of a woman wearing a headband and glasses
Image of woman.
Image of Doctor.
Image of doctor with black hair.
Image of woman with blonde hair.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
a man and a woman in front of a dark blue background
Image of woman with black hair.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
Related Content
Advertisement
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers: © stock.adobe.com.
June 20th 2025

Clinical Trial Corner: New Treatments in Leukemia, Lymphoma and Brain Cancers

Spencer Feldman
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of kelly.
May 23rd 2025

Ovarian Cancer Treatment Side Effects Make for a Difficult Balancing Act

Kelly Irvin
I urge researchers to look into why side effects occur in cancer drugs and to find ways to mitigate them that doesn’t impact their efficacy.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Bonnie Annis is a breast cancer survivor, diagnosed in 2014 with stage 2b invasive ductal carcinoma with metastasis to the lymph nodes. Catch up on all of Bonnie's blogs here!
May 12th 2025

Lymphedema Makes Summer Preparations Challenging After Breast Cancer

Bonnie Annis
Summer heat can worsen my lymphedema, but I’ve learned simple ways to stay cool, reduce swelling and protect my arms — here’s what helps me most.
Clinical Trial
Published: May 5th 2025 | Updated: May 5th 2025

POIESIS Trial Explores Navtemadlin Plus Jakafi for Myelofibrosis

Ryan Scott
The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.
Related Content
Advertisement
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers: © stock.adobe.com.
June 20th 2025

Clinical Trial Corner: New Treatments in Leukemia, Lymphoma and Brain Cancers

Spencer Feldman
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of kelly.
May 23rd 2025

Ovarian Cancer Treatment Side Effects Make for a Difficult Balancing Act

Kelly Irvin
I urge researchers to look into why side effects occur in cancer drugs and to find ways to mitigate them that doesn’t impact their efficacy.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Bonnie Annis is a breast cancer survivor, diagnosed in 2014 with stage 2b invasive ductal carcinoma with metastasis to the lymph nodes. Catch up on all of Bonnie's blogs here!
May 12th 2025

Lymphedema Makes Summer Preparations Challenging After Breast Cancer

Bonnie Annis
Summer heat can worsen my lymphedema, but I’ve learned simple ways to stay cool, reduce swelling and protect my arms — here’s what helps me most.
Clinical Trial
Published: May 5th 2025 | Updated: May 5th 2025

POIESIS Trial Explores Navtemadlin Plus Jakafi for Myelofibrosis

Ryan Scott
The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.